Objective To inquire bacteria distribution and drug resistance trend of Acinetobacter Baumannii, and provide reference of antimicrobial drugs rational for clinical treatment. Methods The bacteria were identified by Automatic Bacterial Identification(MicroScan walkAway-40 by Germany’s Siemens)and Susceptibility Analyzers and susceptibility testing was done at same time. WHONE 5.6 software was used for statistical analysis for 265 Acinetobacter Baumannii. Results The 87% of Acinetobacter Baumannii was from sputum. The department where the bacteria were discovered was Intensive Care Unit. The drug resistance rates of Cefperazone-Sulbactam was lower than 25% in the first,second,third and fourth quarter. The drug resistance rates of Ceftazidine, Ceftriaxone, Cefepime, Piperacillin and Tazobactam, Piperacillin, Compound Sulfamethoxazole, Ciprofloxacin, Amikacin, and Levofloxacin exceed 75% in the first, second and fourth quarter. The drug resistance rates of Ceftazidine, Ceftriaxone, Imipenem, Cefepime, Piperacillin and Tazobactam were 57.1%～66.7% in the third quarter. Irrational use of antibiotics caused the increased resistance in the fourth quarter increased. Conclusion Acinetobacter Baumannii could result in lung’s infections in ICU patients easily. The first choice of treatment drug is Cefoperazone-sulbactam. Hospitals should be strict in implementing disinfection and isolation practice, meanwhile hospitals should use antimicrobial agents to prevent Acinetobacter Baumannii resistant strains from spreading in the hospital. Physicians need to closely follow the surveillance results the resistance in their region, ensure rational use of antibiotics to curb Acinetobacter’s drug resistance rising.